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Key messages
What is the key question?
 ► In patients with an exacerbation of COPD 
triaged for admission, is Hospital at Home 
directed by low-risk DECAF score (0 or 1) 
clinically effective and cost-effective compared 
with usual inpatient care?
What is the bottom line?
 ► Hospital at Home directed by DECAF is 
safe, clinically effective, cost-effective, and 
preferred by 90% of patients. This model 
simplifies selection for Hospital at Home, 
while approximately doubling the proportion 
of patients considered eligible compared with 
previous studies.
Why read on?
 ► The potential clinical and financial benefits 
of widespread implementation of Hospital at 
Home directed by DECAF are large, especially 
given that exacerbation of COPD is the second 
most common reason for hospital admission.
AbsTrACT 
background Previous models of Hospital at Home 
(HaH) for cOPD exacerbation (ecOPD) were limited by 
the lack of a reliable prognostic score to guide patient 
selection. approximately 50% of hospitalised patients 
have a low mortality risk by DecaF, thus are potentially 
suitable.
Methods in a non-inferiority randomised controlled 
trial, 118 patients admitted with a low-risk ecOPD 
(DecaF 0 or 1) were recruited to HaH or usual care (Uc). 
the primary outcome was health and social costs at 90 
days.
results Mean 90-day costs were £1016 lower in HaH, 
but the one-sided 95% ci crossed the non-inferiority 
limit of £150 (ci −2343 to 312). Savings were primarily 
due to reduced hospital bed days: HaH=1 (iQr 1–7), 
Uc=5 (iQr 2–12) (P=0.001). length of stay during the 
index admission in Uc was only 3 days, which was 2 days 
shorter than expected. Based on quality-adjusted life 
years, the probability of HaH being cost-effective was 
90%. there was one death within 90 days in each arm, 
readmission rates were similar and 90% of patients 
preferred HaH for subsequent ecOPD.
Conclusion HaH selected by low-risk DecaF score was 
safe, clinically effective, cost-effective, and preferred by 
most patients. compared with earlier models, selection 
is simpler and approximately twice as many patients are 
eligible. the introduction of DecaF was associated with 
a fall in Uc length of stay without adverse outcome, 
supporting use of DecaF to direct early discharge.
Trial registration number registered prospectively 
iSrctn29082260.
InTroduCTIon
Hospital at Home (HAH) treats patients in their 
home for a condition that would otherwise require 
hospital admission.1 The British Thoracic Society,2 
the National Institute for Health and Care Excel-
lence (NICE)3 and the joint European Respiratory 
Society/American Thoracic Society (ERS/ATS) 
guidelines4 endorse HAH services for patients with 
COPD exacerbation (ECOPD) and recommend 
that selection for such services is based on low acute 
mortality risk. Previous randomised controlled 
trials (RCTs) of domiciliary care for patients with 
ECOPD had extensive and inconsistent inclusion 
and exclusion criteria, partly due to the previous 
lack of a reliable prognostic score to direct selec-
tion of low-risk patients.5 The pressing need for 
prospective research to define optimal criteria for 
patient selection for HAH has been highlighted.4
The DECAF score is a robust predictor of inpa-
tient mortality in patients admitted with ECOPD.6 7 
It has shown consistent, strong performance in 2645 
patients across three cohorts with an area under the 
receiver operator curve of 0.82–0.86. Of impor-
tance, it is simple to score at the bedside using 
indices routinely available on admission (table 1). 
The 2014 UK COPD audit report recommends 
routine documentation of DECAF indices on 
admission.8
Approximately 50% of hospitalised patients have 
a DECAF score of 0 or 1, which is associated with a 
low in-hospital mortality risk (1%–1.4%). Selection 
for HAH by DECAF offers the potential to more 
than double the proportion of eligible patients 
compared with earlier models,5 while simplifying 
the selection process. As ECOPD is one of the 
most common reasons for hospital admission, this 
represents a large absolute number of patients that 
could be treated with HAH, but the effect on cost 
and outcome is unknown.
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Table 1 DECAF score
dECAF score  Circle 
D* eMRCd 5a (too breathless to leave the house unassisted but 
independent in washing and/or dressing)
1
eMRCd 5b (t oo breathless to leave the house unassisted and 
requires help with washing and dressing) 
2
E Eosinopaenia (eosinophils <0.05×109/L) 1
C CXR Consolidation 1
A† Moderate or severe Acidaemia (pH<7.3) 1
F Atrial Fibrillation (including history of paroxysmal AF) 1
Total:
*Breathlessness assessed on a good day within the last 3 months, not 
breathlessness during an exacerbation/on admission.
†If a blood gas has not been performed, provided oxygen saturation breathing 
room air is greater than 92%, acidaemia can be assumed not to score. Please refer 
to the DECAF validation study for detailed instructions on scoring.7
AF, atrial fibrillation; CXR, chest radiograph; eMRCD, extended Medical Research 
Council Dyspnoea score.
Table 2 Minimisation indices
ABG (management 
pathway)
PaCO2 ≤6 + pH ≥7.35 PaCO2 >6 + pH ≥7.35 pH <7.35
Hospital admissions in 
the previous year
0 1 2 or more
Prior social care (private 
or social services)
None Social care
eMRCD score 1–4 5a
Cerebrovascular disease Yes No
ABG, arterial blood gas; eMRCD score, Extended Medical Research Council 
Dyspnoea score. 
Accurate prediction of outcome may direct treatment choices 
and improve outcomes9; however, clinical judgement alone is 
suboptimal.10 Before prognostic scores are adopted in routine 
practice, clinical impact studies assessing outcomes and cost-ef-
fectiveness are recommended, although these are seldom 
performed.9 We have undertaken an RCT with an economic 
evaluation (cost-effectiveness analysis) comparing HAH with 
usual care (UC) in patients admitted with a low-risk ECOPD 
selected by DECAF score. The trial examined whether, within 
a non-inferiority limit of £150, the total health and social care 
costs up to 90 days associated with HAH are the same or less 
than those from UC. Clinical outcomes included length of 
hospital stay (LOHS), readmission rates, mortality and health-re-
lated quality of life.
METhods
study design and patients
In a non-inferiority RCT, eligible patients with a low-risk 
(DECAF 0–1) ECOPD11 admitted to one of three hospitals 
within one Trust underwent 1:1 allocation to HAH or UC and 
were followed for 90 days from presentation. In the UK health-
care system, a National Health Service Trust is an organisation 
that serves a geographical region, in this instance a socioeco-
nomically diverse urban and rural population, with the largest 
geographical footprint in England. The COPD population has 
high rates of social deprivation and comorbidity.7 8 Ninety days 
was chosen for the primary outcome because this is the key risk 
period for readmission.12
Eligibility criteria included low mortality risk (DECAF 0–1), 
age 35 years or older, 10 or more smoking pack-years, and 
pre-existing or admission obstructive spirometry.11 Inpatient 
spirometry was only performed in individuals with a pre-existing 
COPD diagnosis where confirmatory spirometry was unavailable 
(eg, inaccessible general practitioner (GP) records on weekends) 
or in those with a high pretest probability of a new diagnosis of 
COPD. Patients were excluded if they had an illness (other than 
COPD) likely to limit survival to less than 1 year, were on long-
term ventilation, had a coexistent secondary diagnosis necessi-
tating admission, were assessed more than one overnight stay 
after admission or could not provide written informed consent. 
Patients were not eligible to enter the trial from the emergency 
department to ensure only admitted patients were included.
All patients who met the entry criteria were offered partici-
pation, including DECAF 1 patients with coexistent pneumonia 
or acidaemia. All patients were analysed in their original allo-
cated group, even if the consultant decided that an HAH patient 
should stay in the hospital. Baseline data were collected prior 
to treatment allocation. In the HAH arm, patients readmitted 
during follow-up with a low-risk ECOPD were offered HAH 
while all other readmissions were managed according to UC.
randomisation and masking
Allocation to HAH or UC was based on 1:1 randomisa-
tion, performed by minimisation13 (table 2) undertaken by an 
external, independent agency ( sealedenvelope. com). Individual 
patients had a 30% chance of allocation purely by random 
number sequence; the researchers were blind to the method of 
allocation for individual patients. For the primary cost analysis, 
the health economist was blinded to group allocation.
Procedures
HAH treatment
HAH treatment replaces all or most of the hospital admission 
and requires that patients are not sufficiently well for discharge, 
resulting in a more unwell population than seen in early 
supported discharge (ESD) services.
In our HAH model, patients were admitted to hospital, iden-
tified as low risk by DECAF, and then returned home under the 
care of the hospital respiratory team, usually within 24 hours of 
admission. The HAH treatment period ended when the respi-
ratory specialist nurse (RSN) and consultant deemed that the 
patient was sufficiently well for discharge to the care of the GP, 
typically after 5 days.
Patients received once or twice daily visits from an RSN, under 
remote supervision from a respiratory consultant. An emergency 
contact number allowed patients to contact the team 24 hours 
a day, 7 days a week. Physiological parameters were monitored 
daily and blood sampling (including arterial blood gas anal-
ysis) taken as required. Oral and intravenous therapies, acute 
controlled oxygen therapy, physiotherapy, psychology, occupa-
tional therapy and formal social care were available at home.
Patients randomised to HAH could return home imme-
diately provided the initial arterial pH was 7.35 or more and 
PaCO2 was 6 kPa or less. Patients with PaCO2 greater than 6 kPa 
without acidaemia could return home after one overnight stay 
in hospital, provided they were not deteriorating. Patients with 
acidaemia could return home the day that followed resolution of 
the acidaemia and, if initiated, once non-invasive ventilation was 
complete. This ‘ABG management pathway’ was included as one 
of the minimisation indices.
Return to hospital during HAH was not considered a readmis-
sion, but rather an increase in level of care. If return to hospital 
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Table 3 Key unit costs
Type of unit cost source Cost (£)
A+E attendance NHS reference costs 2015 90.2–377.9
Outpatient clinics NHS reference costs 2015 39.7–215.4
Respiratory clinic NHS reference costs 2015 165.9
Bed days, admissions unit Healthcare Trust 294.9 per day
Bed days, medical ward Healthcare Trust 246.2 per day
Bed days, rehabilitation 
ward
Healthcare Trust 168.8 per day
Doctor, consultant time PSSRU unit costs of 
health+social care 2015
153 per hour
Doctor, registrar time PSSRU unit costs of 
health+social care 2015
68.4–75 per hour
Doctor, F1–ST2 PSSRU unit costs of 
health+social care 2015
42.5–67 per hour
Respiratory specialist nurse PSSRU unit costs of 
health+social care 2015
46.2–68.6 per hour
Physiotherapy PSSRU unit costs of 
health+social care 2015
39.2–49.5 per hour
A+E, accident and emergency; NHS, National Health Service; PSSRU, personal social 
services research unit.
during HAH were considered a readmission, this could create 
bias because patients in UC are hospitalised and therefore not 
exposed to the risk of readmission.
Further details of the HAH service are available in the HAH 
manual and review sheets in online supplementary files 1, 2 and 
3. The manual has been updated following service feedback, but 
the interventions and procedures are unchanged from those used 
in the trial.
Usual care
This included usual measures to ensure the prompt discharge 
of patients with ECOPD, such as supported discharge by RSNs. 
Based on local data from 492 patients scoring DECAF 0 or 1 
prior to the trial, we anticipated that the median LOHS would 
be 5 days. The decision to discharge patients in the UC group 
was made by the attending clinician.
outcomes
The primary outcome was the total cost of health and formal 
social care over 90 days from presentation, costed from a UK 
health and social care perspective. The secondary outcomes 
were survival, readmission rate, total bed days over 90 days 
and cost-effectiveness, using the EuroQuality of life instrument 
(EQ-5D-5L) quality-adjusted life year (QALY) measured at base-
line, 14 and 90 days,14 patient preference for HAH or UC (as 
a binary question at 14 days), COPD exacerbations, Hospital 
Anxiety and Depression Scale scores (HADS), and COPD Assess-
ment Tool (CAT) scores.
All costs, unless stated otherwise, were recorded at the 
patient level by multiplying patient-level resource use by the 
appropriate unit cost, and the average costs per treatment arm 
were subsequently estimated. Data collection was the same in 
both arms, except for resource collection during HAH treat-
ment (‘HAH visits and travel time’ and ‘telephone call costs’). 
All visiting health and social care staff recorded time spent 
with the patient and travel time, including interactions outside 
of usual work hours. This was triangulated with a time and 
motion study performed by RSNs in a subpopulation of HAH 
patients.
Patients in both arms maintained a diary of all health and social 
care visits and attendances, and were phoned every 2 weeks to 
prompt completion and collect data. These data were cross-refer-
enced with primary, secondary and social care records to provide 
costs for ‘formal social care’, ‘home visits after discharge’ and 
‘A+E and outpatient appointments’. Additional consent was 
gained for remote monitoring of health and social records if the 
patient withdrew from the trial, allowing complete data capture.
For primary care, resource use included all medications, GP 
appointments, and home visits by doctors and allied healthcare 
professionals.
Secondary care inpatient costs considered specific to DECAF 
0–1 patients were costed at the patient level. This included inpa-
tient healthcare reviews, medications, laboratory and diagnostic 
costs, oxygen use, non-invasive ventilation use and LOHS. All 
‘inpatient healthcare reviews’ were recorded, including those by 
doctors, specialist nurse and physiotherapists; this was costed 
based on the seniority of the individual and the amount of time 
spent with the patient. Where unavailable, the time spent with 
the patient was estimated based on the type of encounter (such 
as ‘physiotherapy chest clearance’) and the average time taken 
for similar encounters; all assumptions were the same across 
both arms, and assumptions regarding the type of encounter 
were performed blind to group allocation.
The remaining inpatient costs are those that we expected 
would be similar between patients and/or were not possible to 
separate out at the patient level, for which an average bed day 
cost was calculated. The cost of a day on a ward was costed 
using data from the Trust’s finance department. This included 
running costs (including catering, laundry, gas and electricity), 
staff costs (such as support staff), equipment (medical, surgical 
and non-medical) and associated services (such as phlebotomy). 
These costs were not patient-specific and were assumed the same 
regardless of patients’ characteristics. This was performed sepa-
rately to give a cost for the admissions unit, medical ward and 
rehabilitation ward.
All outpatient visits and accident and emergency attendances 
were recorded.
Social care resource use, including formal social care and 
equipment costs, was obtained from individual social care 
records.
Unit costs were obtained from a variety of national and local 
sources and are reported in online supplementary file 4 for the 
financial year 2015 (£), with key unit costs shown in table 3.
statistical analysis
The primary outcome was the mean difference between HAH 
and UC in total health and social care costs over 90 days. 
HAH was deemed non-inferior to UC if the upper limit of the 
one-sided 95% CI for the primary outcome was less than the 
non-inferiority limit. CIs were calculated with 1000 bootstrap 
replications. For the breakdown in costs (table 7), two-sided 
95% CIs were calculated.
The non-inferiority limit and the power calculation were 
based on the best available data, which were limited to health 
costs for the index admission. Based on tariff costs received by 
the Trust for 373 patients admitted with DECAF 0–1 ECOPD, 
the estimated SD of costs was £1143, and HAH costs were esti-
mated as £470 less expensive per patient compared with UC. 
One hundred and eighteen patients were required to be 90% 
sure that the upper limit of a one-sided 95% CI would be below 
the non-inferiority limit of £150, if the true difference in costs 
were 0.15 This threshold was discussed with hospital managers, 
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Figure 1 CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials; HAH, Hospital at Home. 
who confirmed that if HAH was £150 more expensive than UC 
this would not prevent them from financially supporting the 
implementation of HAH services.
The outcome measure used in the economic analysis was 
the QALY. Health-related quality of life was assessed using 
the EQ-5D-5L questionnaire, which is valid and responsive in 
COPD,16 and a standard algorithm was used to obtain utility 
scores.17 The QALY was obtained by linear regression estima-
tion, controlling for intervention groups and baseline utility 
using the area under the curve approach (individual QALYs were 
calculated by taking the mean value between measurements and 
multiplying this with time).18 The cost-effectiveness plane and a 
cost-effectiveness acceptability curve were derived from the joint 
distribution of incremental costs and incremental QALYs using 
non-parametric bootstrapping of the observed data.
Bed days were compared using Mann-Whitney U test with 
a two-sided P value of <0.05 regarded as significant. Primary 
analyses were performed with complete case analysis. A sensi-
tivity analysis was performed using multiple imputation, with 
missing data assumed to be missing at random, to create five 
data sets19 using the Markov chain Monte Carlo method. All 
baseline patient characteristics and outcomes were included 
in the imputation model. Data were analysed using IBM SPSS 
V.22 statistics and Stata V.14. Patients allocated to HAH who 
received UC treatment were analysed in their original allocation 
group as per the intention-to-treat principle. In a prespecified 
safety analysis, deaths and readmissions were reported per 
protocol.
The funders had no role in data collection, analysis or in 
writing of the report. During the review process, we agreed 
to make our prespecified cost outcome the primary measure, 
replacing total bed days over 90 days.
rEsulTs
Emergency hospital admissions from June 2014 to January 2016 
were reviewed to ensure all patients with ECOPD were iden-
tified. Of note, 64 patients with a DECAF 0–1 ECOPD were 
planned for same-day discharge before eligibility assessment and 
were not included because HAH is not indicated for those who 
are sufficiently well for discharge. Of 207 DECAF 0 or 1 ECOPD 
assessed for eligibility, 120 were randomised. Two patients who 
did not meet the eligibility criteria were randomised in error and 
were not included in the primary analysis. In both instances, this 
was recognised and the patients were removed within 30 min of 
randomisation. Three patients were randomised to HAH, but 
were intentionally treated by UC, and were analysed in their 
original allocation as per the intention-to-treat principle (see 
figure 1). Groups were well matched with respect to minimisa-
tion indices (table 4).
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Table 4 Baseline characteristics of patients
hAh, n=60 uC, n=58
DECAF indices
  DECAF score 1, n (%) 43 (71.7) 31 (53.4)
  eMRCD dyspnoea score 5a, n (%) 
repeat below
12 (20) 9 (15.5)
  Eosinopaenia, % 15 (25) 8 (13.8)
  CXR consolidation, % 15 (25) 9 (15.5)
  Acidaemia (pH <7.30), % 1 (1.7) 0
  Atrial fibrillation, % 0 0
Minimisation indices
  ABG management, pH <7.35 / 
PCO2 >6 pH ≥7.35, %
7 (11.7) / 40 (66.7) 8 (13.8) / 38 (65.5)
  Hospital admissions in the previous 
year 1 / 2, %
12 (20) / 21 (35) 12 (20.7) / 19 (32.8)
  Prior social care, % 3 (5) 1 (1.7)
  Cerebrovascular disease, % 9 (15) 9 (15.5)
Sociodemographics
  Age, years* 71.0 (9.6) 68.7 (10.5)
  Female, % 32 (53.3) 30 (51.7)
  Smoking pack-years, n† 45 (35–50) 44 (30–60)
  Current smoking, % 27 (45) 25 (43.1)
  Reporting no qualifications on 
leaving school, %
46 (76.7) 41 (70.7)
  Most frequently reported family 
income per year, £†
5200–10 399 10 400–15 599
Markers of disease severity
  FEV1% predicted* 45.5 (18.4) 42.1 (16.3)
  LTOT prior to admission, % 7 (11.7) 2 (3.4)
  Cor pulmonale, % 11 (18.3) 5 (8.6)
Comorbidity
  IHD, % 14 (23.3) 12 (20.7)
  Diabetes, % 8 (13.3) 5 (8.6)
  LVD, % 1 (1.7) 3 (5.2)
  Anxiety, % 9 (15.0) 3 (5.2)
  Depression, % 12 (20.0) 9 (15.5)
Admission clinical data
  Respiratory rate, per minute* 25 (4.5) 26 (5.1)
  Pulse rate, per minute* 103.9 (19.6) 104.9 (15.4)
  sBP, mm Hg* 140.8 (21.1) 145.1 (24.3
  dBP, mm Hg* 77.3 (12.2) 80.9 (14.5)
  Temperature, °C† 36.6 (36.2–37.3) 36.5 (36.1–37.1)
  Oxygen saturation† 92 (89–94) 92 (88.5–95)
  Discoloured sputum, % 43 (71.7) 33 (56.9)
Arterial blood gas values
  pH† 7.42 (7.39–7.45) 7.42 (7.38–7.44)
  PaO2, kPa† 7.6 (7.2–9.3) 7.9 (7.2–10.2)
  PaCO2, kPa† 5.5 (5–6.25) 5.3 (4.8–6.6)
  HCO3, mmol/L* 27.1 (4.3) 27.3 (4.7)
  pH <7.35, % 7 (11.7) 8 (13.8)
Baseline outcome measures
  Utility score (EQ-5D-5L), n* 0.517 (0.268) 0.501 (0.243)
Continued
hAh, n=60 uC, n=58
  Hospital Anxiety and Depression 
Scale score A / D, n†
6 (4–10.25) / 7 (4–9) 7 (4–10) / 5 (2–8.25)
  COPD Assessment Tool, n† 28.5 (21.75–33) 27 (23–32.25)
Treatment
  ECOPD treatment prior to 
admissions, %
32 (53.3) 26 (44.8)
*Mean (SD).
†Median (IQR).
A/D, anxiety/depression; ABG, arterial blood gas; CXR, chest radiograph; dBP, 
diastolic blood pressure; ECOPD, COPD exacerbation;  eMRCD, extended Medical 
Research Council Dyspnoea score;  EQ-5D-5L, EuroQuality of life; HAH, Hospital at 
Home; HCO3, bicarbonate; IHD, ischaemic heart disease; LTOT, long-term oxygen 
therapy; LVD, left ventricular dysfunction; sBP, systolic blood pressure; UC, usual 
care.
Table 4  Continued
Table 5 Mortality, length of stay, readmission, appointments and 
social care, and treatment preference outcome
hAh, n=60 uC, n=58
Death at 14 days, n (%) 0 (0) 0 (0)
Death at 90 days, n (%) 1 (1.7) 1 (1.7)
Length of hospital stay at 90 days, median 
(IQR)
1 (1–7) 5 (2–12)*
Length of hospital stay at 90 days, mean 
(SD)
6.1 (9.7) 10.3 (15.8)
Length of hospital stay (index admission), 
median (IQR)
1 (1–1) 3 (2–4.25)
Length of hospital stay (index admission), 
mean (SD)
1.2 (2.1) 4.1 (4.6)
Length of stay within HAH, median (IQR) 4 (2–5) NA
Patients with one or more hospital 
readmissions, n (%)
22 (36.7) 23 (39.7)
Patients with one or more A+E attendances 
post discharge, n (%)
29 (48.3) 26 (44.8)
Patients with one or more GP attendances 
post discharge, n (%)
26 (43.3) 30 (51.7)
Patients with one or more secondary care 
appointments, n (%)
48 (80.0) 41 (70.7)
Patients with a social care package post 
discharge, n (%)
7 (11.7) 5 (8.6)
Stated preference for HAH care day 14, 
n (%)
54 (90.0) 51 (87.9)
*P=0.001 using Mann-Whitney. For bed days over 90 days, based on length of stay 
from 373 patients, 116 patients were needed to detect a difference of 4.7 days with 
90% power assuming a type 1 error rate of 5% in a superiority analysis.
A+E, accident and emergency; GP, general practitioner; HAH, Hospital at Home; NA, 
not applicable; UC, usual care. 
Clinical outcomes
There were no deaths in the acute period (within 14 days) in 
either arm. Within 90 days, there was one death in each arm. 
There was a statistically significant reduction in bed days over 90 
days in those treated with HAH (HAH=1, IQR 1–7 compared 
with UC=5, IQR 2–12; P=0.001). Readmission rates were 
similar in both arms, with 22 (36.7%) in HAH and 23 (39.7%) 
in UC (table 5).
At 14 days, 90% of patients across both arms stated they would 
prefer HAH treatment during future exacerbations of similar 
severity (HAH=54 of 60; UC=51 of 57). In the prespecified, 
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Table 6 Changes in quality of life and HADS scores from baseline
hAh uC
unit change* % MCId† Missing unit change % MCId Missing
HADS-A 14-day (IQR) −1.0 (−3 to 1.75) 48.3 0 0.5 (−3 to 2) 33.9 2
HADS-A 90-day (IQR) 0 (−2 to 3) 33.3 6 0 (−3 to 2) 38.2 3
HADS-D 14-day (IQR) −1.0 (−3 to 1) 38.3 0 0 (−2 to 3) 26.8 2
HADS-D 90-day (IQR) −0.5 (−3 to 1.25) 37.0 6 0 (−2 to 3) 27.3 3
CAT 14-day (IQR) −4.0 (−9.5 to 0) 61.7 0 −3.0 (−7 to 1) 57.9 1
CAT 90-day (IQR) −3.0 (−8 to 1) 51.9 6 −1.0 (−6 to 1) 36.4 3
Utility 14-day (EQ-5D-5L) (SD) 0.091 (0.249) 56.7 0 0.055 (0.316) 49.1 1
Utility 90-day (EQ-5D-5L) (SD) 0.003 (0.287) 43.9 3 0.007 (0.338) 41.1 2
*Values are median, except utility which is mean. Unit change is the difference in absolute values between follow-up and baseline. Improvements in health status are negative 
for HADS and CAT, and positive for utility scores.
†The percentage of patients who improved by an MCID, which is 1.5 for HADS-A and HADS-D,21 2 for CAT and 0.051 for the EQ-5D-5L.20
CAT, COPD Assessment Tool; EQ-5d-5L, Euro Quality of life instrument; HADS, Hospital Anxiety and Depression Scale; HAH, Hospital at Home; MCID, minimally clinically important 
difference; UC, usual care. 
Figure 2 Length of stay and cost difference (£) between HAH and UC. One-sided CIs for the mean difference in 90-day health and social care costs 
between UC and HAH are shown for the trial population (UC=3 days) and the sensitivity analysis adjusting for a longer hospital stay in UC (UC=4 
days and UC=5 days); Δ=£150, α=£340. HAH, Hospital at Home; UC, usual care.  
per-protocol safety analysis, deaths were unchanged (one in each 
arm at 90 days), and there were 21 of 57 (36.8%) readmissions in 
HAH and 23 in 58 (39.7%) in UC. Table 6 shows the change in 
quality of life scores from baseline at 14 days and 90 days as the 
unit change and as the per cent of patients who improved by a 
minimally clinically important difference (MCID). Further data on 
utility scores are available in online supplementary table e10.
For HADS and CAT, negative values represent improvements 
in health from baseline, while for utility scores, positive values 
represent improvements from baseline. The improvements in 
health status in HAH compared with UC were clinically mean-
ingful for HADS-anxiety score at 14 days and CAT at 90 days, 
but this could be a chance finding.20 21 On multiple imputation 
the difference in the benefit of CAT at 90 days was 1.5, but 
the utility score at 14 days was 0.51, which is above the MCID 
(online supplementary table e11).
Cost and cost-effectiveness analysis
The mean health and formal social care cost over 90 days was 
£1016 lower in HAH than in UC. However, there was wide 
variation in costs and the one-sided 95% CI crossed both the 
no effect limit (0) and the prespecified non-inferiority limit of 
£150 (figure 2, ‘UC=3 days’: CI −2343 to 312). The cost differ-
ence and distribution were substantially greater than anticipated, 
and so a post-hoc analysis was performed with an adjusted 
non-inferiority limit of £340,15 which was achieved (see figure 2 
and the Discussion section).
During the index admission, the median LOHS in UC was 
3 days, which was 2 days less than expected7 and greater than 
seen in most UK hospitals for unselected ECOPD.8 We performed 
a prespecified sensitivity analysis to assess the effect of LOHS 
in UC during the index admission on health and formal social 
care costs. One additional bed day without medical staffing costs 
would increase the mean cost difference to −£1262 with a one 
sided 95th percentile of £66, achieving the prespecified non-in-
feriority limit of £150. Two bed days would have been −£1508 
with a one-sided 95th percentile of −£180.
The difference in cost was primarily related to inpatient and 
formal social services costs (table 7). The costs of the index 
admission alone are shown in online supplementary table 
e12. Total QALY scores were non-significantly higher in HAH 
compared with UC. The mean total QALYs (SD) adjusted for 
baseline utility were 0.138 (0.052) for HAH and 0.133 (0.052) 
for UC, giving a small difference of 0.005 (95% CI −0.14 to 
0.25). Unadjusted and Multiple Imputation (MI) analyses of 
QALYs are shown in online supplementary table e10. The prob-
ability of HAH being cost-effective compared with UC was 90% 
at the NICE threshold of £30 000 per QALY. This is the propor-
tion of dots beneath the diagonal line in figure 3A, and is repre-
sented by the vertical line in figure 3B. HAH was both cheaper 
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Table 7 Health and formal social care average costs at 90 days
overall costs hAh, £ (sd) uC, £ (sd) bootstrapped mean difference (£) bootstrapped 95% CI* of cost difference
  Health and formal social care 3857.8 (3199.6) 4873.5 (5631.1) −1015.7 −2735.5 to 644.8
  Healthcare 3819.2 (3135.0) 4755.8 (5525.4) −936.6 −2645.4 to 709.9
  Oxygen therapy 38.4 (68.4) 18.3 (53.7) 20.1 −1.73 to 42.0
  Medication 422.5 (275.2) 458.9 (331.4) −36.4 −150.1 to 75.7
Hospital costs
  Bed stay 1540.8 (2000.7) 2775.2 (4129.6) −1234.4 −2524.8 to −82.0
  Inpatient healthcare review 417.7 (399.1) 514.3 (650.7) −96.7 −288.4 to 96.4
  Laboratory and diagnostic tests 375.1 (383.8) 358.7 (422.4) 16.4 −128.1 to 169.1
  NIV costs 44.4 (261.0) 158.2 (436.2) −113.8 −255.4 to 8.12
HAH costs
  HAH visits and travel time† 383.9 (276.0) 0.0 (0.0) 383.9 319.2 to 455.3
  Telephone calls costs 5.8 (14.2) 5.4 (10.8) 0.5 −3.57 to 5.33
Community costs
  Formal social care 38.6 (173.1) 117.7 (711.0) −79.0 −299.2 to 55.2
  Home visits after discharge 43.7 (87.7) 39.2 (55.7) 4.5 −19.2 to 31.8
  A+E and outpatient 
appointments
546.8 (347.5) 427.6 (394.9) 119.2 −22.6 to 243.0
*The 95% CI in the table is two-sided (0.025 to 0.975), calculated with the bootstrap approach. For health and formal social care (the primary outcome), the one-sided 95% CI 
(0.95) was £312.
 †55% of time on HAH visits was spent with the patient (45% on travel time).
A+E, accident and emergency; HAH, Hospital at Home; NIV, non-invasive ventilation; UC, usual care. 
Figure 3 Cost-effectiveness plane (A) and cost-effectiveness acceptability curve (B). The cost-effectiveness plane for HAH and UC, with the diagonal 
line representing the NICE cut-off at £30 000 per QALY. Area 1=HAH cheaper and more effective; area 2=HAH more effective and more expensive but 
less than the NICE cut-off; and area 3=UC is more effective but more expensive and exceeds the NICE cut-off. (B) The probability of cost-effectiveness 
is shown over a range of willingness to pay for a QALY, to inform decisions to accept or reject new technologies. There is a 90% probability HAH will 
be cost-effective at the NICE threshold (vertical line). HAH, Hospital at Home; NICE, National Institute for Health and Care Excellence; QALY, quality-
adjusted life year; UC, usual care. 
and more effective for most patients treated (74% probability). 
Similar results were seen using multiple imputation (online 
supplementary figure E1). Of note, the Cost Effectiveness plane 
shows high uncertainty around the incremental cost difference, 
although little uncertainty around the incremental effectiveness 
estimates.
hAh and inpatient interactions
Of the 60 patients allocated to HAH, 53 (88.3%) had a 0 or 1 day 
stay. Most patients incurring an overnight stay were admitted in 
the afternoon or evening. The period of HAH lasted a median of 
4 (IQR 2–5) days per episode. Including travel time, healthcare 
professionals spent a median of 7.2 hours (IQR 4.7–10.8) on 
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home visits per HAH spell (median RSN visits=7.1 hours, IQR 
4.4–10.1). There were 342 visits for 57 episodes: RSN=327, 
physiotherapy=13, psychology=1 and respiratory support 
worker=1. During HAH, two patients returned to hospital for 
assessment (which included a respiratory consultant review, 
repeat chest radiograph and blood testing) and returned home 
the same day. One patient returned to hospital and stayed over-
night before returning home to complete their HAH spell.
The number of inpatient interactions with any healthcare 
worker was 1158 for HAH (1500 including inpatient interac-
tions, or 25 interactions per patient) and 1558 for UC (or 27 
interactions per patient). In part, the increased numbers of inpa-
tient interactions for UC were due to reviews by doctors and 
physiotherapists (see online supplementary table e13).
Patients declining participation
As part of an audit of practice, the baseline characteristics of 
patients who declined to participate in the HAH study were 
reviewed. Patients who declined enrolment were not more unwell 
than study participants based on comorbidity and measures of 
disease severity (online supplementary table e14).
dIsCussIon
In an economic evaluation, HAH selected by DECAF was more 
cost-effective than UC, primarily driven by a fivefold reduction 
in median hospital bed days over 90 days, with a small non-sig-
nificant difference in QALYs favouring HAH. The percentage 
of patients improving by the MCID was numerically higher in 
HAH compared with UC for seven of eight outcomes measuring 
health status.
The potential cost savings are substantial as ECOPD is one 
of the most common reasons for hospital admission and up to 
50% of patients are potentially eligible (DECAF 0–1). In both 
arms, there were no deaths within the acute period, and read-
mission rates over 90 days were comparable in intention-to-treat 
and per-protocol analyses. Crucially, 90% of patients across 
both arms stated they would prefer HAH to UC for future 
exacerbations of similar severity. The DECAF score allows 
low-risk patients to be identified quickly and safely using indices 
routinely captured on admission, facilitating replication of our 
model of HAH. This meets the major research need identified by 
the ERS/ATS to better define patient selection criteria for HAH.4 
Of importance, use of DECAF was associated with reduction in 
LOHS within UC of at least 2 days, without adverse outcome. 
This supports use of a low-risk DECAF score to select patients 
for early discharge, which may be implemented in advance of 
establishing a full HAH clinical service.
This study has several strengths. We assessed the impact of using 
the DECAF score to direct HAH treatment, replicating how we 
anticipate the tool will be used in clinical practice. Such imple-
mentation studies are extremely rare despite being strongly recom-
mended.9 We performed a detailed and extensive cost analysis, 
recording all important aspects of health and social care with low 
rates of missing data. We included several important measures of 
health status which the ERS/ATS reported is lacking in previous 
studies,4 and methods of patient allocation and handling of missing 
data were robust. Patients were randomised by minimisation, 
which ensures excellent balance for selected prognostic indices.13 22 
The likelihood of allocation to an intervention is influenced by the 
current distribution of subjects and weighted minimisation indices. 
To avoid potential selection bias, 30% of allocations were by 
simple randomisation and the researchers were blinded to the allo-
cation process, performed by an independent agency. The HAH 
service included all members of the usual multidisciplinary team 
and important aspects of care such as smoking cessation, inhaler 
training, breathing exercises and the offer of early pulmonary 
rehabilitation.
One of the key limitations of the study was the choice of £150 as 
the non-inferiority limit, which meant that HAH did not meet the 
chosen non-inferiority limit. First, this occurred because the data 
were only available for a single admission, and not for the primary 
outcome of total health and social care cost over 90 days. The actual 
mean total cost over 90 days in UC was far higher than anticipated 
at £4874, so a non-inferiority limit of £150 was overly conser-
vative. It is usual in non-inferiority studies to choose a margin 
that reflects the largest loss that would be acceptable.23 In the 
context of a higher mean difference, a larger non-inferiority limit 
is appropriate. Non-inferiority limits should be based on statis-
tical reasoning and clinical judgement. In our post-hoc analysis a 
non-inferiority limit to £340 was selected. Statistically, we chose 
this value as it is one-third of the cost difference between arms, 
which is the same ratio as the original non-inferiority limit and 
estimated cost difference. The acceptability of this non-inferiority 
limit is confirmed by the fact that this model of HAH has subse-
quently been commissioned. Second, the cost difference between 
HAH and UC may have been affected by a reduction in LOHS in 
UC. The number of patients unsuitable for HAH (because they 
already had same-day discharge plans) was larger than expected, 
resulting in a more unwell and costly study population. This 
should have resulted in an increased median LOHS in UC, but it 
was 2 days lower than expected. Non-exclusion of more unwell 
patients with longer LOHS could theoretically account for this. 
However, this is unlikely as the short stay group (n=64) was larger 
than the excluded group (n=50), and would have had a bigger 
impact on the median value. Furthermore, those who declined 
participation in the study were not more unwell than study partic-
ipants. The most likely explanation is that the use of the DECAF 
score and study participation reduced LOHS. Only UC patients 
expressed disappointment with their allocated arm, knowledge 
of participation may have influenced clinician behaviour and bed 
pressures may have exerted additional influence.
Despite a large proportion of patients improving by the MCID 
(table 6), baseline and 90-day follow-up quality of life scores 
were similar across the whole population. This apparent discrep-
ancy may be explained by worsening health status in those who 
were readmitted. In those who suffered an overall deteriora-
tion in utility score at 90 days, the proportion with one or more 
admissions was 2.5-fold higher.
The results of the study require validation in other healthcare 
systems. The structure of care, including availability of ESD, 
differed between sites and the DECAF score has previously effec-
tively identified low-risk patients in six different hospitals, with 
different populations and structures of care.7 This supports the 
generalisability of the results to other UK hospitals. Some hospi-
tals may currently lack the nursing infrastructure to deliver HAH 
selected by DECAF, but investment is justified as there is a 90% 
chance of this model being cost-effective at both the NICE and 
commonly cited US thresholds, with further possible cost savings 
through reduced LOHS in UC. Training costs of nurses were 
included in our analysis. Finally, 90-day follow-up was selected 
because this is the critical time period for readmission,12 although 
a longer time period of up to 1 year may have been preferable to 
identify a difference in readmission rates between groups.
Meta-analyses of previous studies considered HAH and ESD 
together. These showed that HAH/ESD report reduced readmis-
sion rates and a trend towards a lower mortality with limited 
evidence for an effect on health-related quality of life.5 24 Three 
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studies performed cost analyses showing that HAH/ESD was 
less expensive.25–27 Goossens28 and others performed a detailed 
economic evaluation: at 3 months HAH/ESD was €168 less 
expensive than UC from a healthcare perspective, but €908 
more expensive when societal costs were included. These 
previous studies are primarily of ESD services rather than HAH, 
and comparison with our study should be guarded. For example, 
in the study by Goossens and others, length of stay in the ESD 
treatment arm was the same as our UC arm.
Previous studies of HAH/ESD had extensive eligibility criteria 
to identify suitable, low-risk patients and typically excluded those 
with coexistent pneumonia and acidaemia on blood gas.25 26 29–33 
Ordinarily, clinicians would be reluctant to allow these patients into 
HAH/ESD services, but we treated such patients successfully with 
no difference in mortality between groups. This result is consistent 
with findings from the DECAF derivation and validation study, 
which showed that patients with a low-risk DECAF score and 
pneumonia or acidaemia had a low acute mortality risk.6 7
This RCT shows that HAH selected by low-risk DECAF 
score is safe, clinically effective, preferred by most patients and 
cost-effective compared with UC in this clinical setting. DECAF 
has proven a robust tool in the gold standard of derivation, 
validation and implementation studies, and can be used in clin-
ical practice to select low-risk patients for HAH services. Based 
on this result, our commissioners and the Trust have agreed to 
the implementation of a full clinical service. 
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